PDCD1 and hepatocellular carcinoma: Furthermore, we explored whether triple immunotherapy with anti-LAG-3 mAb, anti-PD-1 mAb, and STING agonists can significantly enhance antitumor immune responses, thus improving the efficacy of HCC immunotherapy.